RVTY
Revvity Inc
NYSE · Life Sciences Tools & Services
$101.59
+2.07 (+2.08%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 2.78B | 2.92B | 9.64B | 9.95B | 9.42B |
| Net Income | 234.54M | 221.78M | 505.26M | 559.12M | 450.80M |
| EPS | — | — | — | — | — |
| Profit Margin | 8.5% | 8.0% | 5.2% | 5.6% | 4.8% |
| Rev Growth | -4.8% | -4.8% | +20.2% | +15.3% | +12.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 1.77B | 1.77B | 2.75B | 3.48B | 3.04B |
| Total Equity | 3.99B | 3.99B | 5.66B | 5.58B | 6.26B |
| D/E Ratio | 0.44 | 0.44 | 0.49 | 0.62 | 0.49 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 725.55M | 724.18M | 975.96M | 873.56M | 871.70M |
| Free Cash Flow | — | — | 387.20M | 503.74M | 344.62M |